<DOC>
	<DOC>NCT00880269</DOC>
	<brief_summary>This study was to evaluate the efficacy and safety of single agent oral panobinostat in patients who have refractory de novo or refractory secondary AML.</brief_summary>
	<brief_title>Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Written informed consent prior to studyspecific screening procedures Life expectancy of ≥ 60 days Eastern Cooperative Group (ECOG) performance status ≤ 2 Refractory AML with confirmed initial diagnosis of de novo AML (excluding APL) OR Refractory AML with confirmed initial diagnosis of AML (excluding APL) secondary to AHD or MDS with either condition precedent to AML (MDS/AHD) Negative serum pregnancy test (within 7 days of first dose) Negative urine pregnancy test immediately prior to first dose Known HIV Psychiatric disorder that interfered with ability to understand the study and give informed consent, and/or would impact study participation or followup Concurrent use of medications that might prolong the QT interval or of inducing Torsade de Pointes Female patients who were pregnant or breastfeeding or patients of childbearing potential who were not willing to use a double barrier method of contraception during the study and for 3 months following the last dose of study drug. Male patients whose sexual partner(s) were women of childbearing potential who were not willing to use a double method of contraception, one of which included a condom, during the study and for 3 months after the end of treatment Patient unable to swallow capsules Patients with impaired gastrointestinal systems which might cause interference with digesting and absorbing panobinostat Other Protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>relapsed acute myeloid leukemia</keyword>
	<keyword>refractory AML</keyword>
	<keyword>refractory de novo AML</keyword>
	<keyword>refractory secondary AML</keyword>
	<keyword>secondary AML</keyword>
	<keyword>AML following myelodysplastic syndrome (MDS)</keyword>
	<keyword>AML following antecedent hematological disorder (AHD)</keyword>
	<keyword>AML resistant to therapy</keyword>
</DOC>